Form 4: Hyperfine Director Jonathan Rothberg Receives Stock Options
Statement of Changes in Beneficial Ownership
Director and 10% owner Jonathan M. Rothberg was granted 157,700 stock options in Hyperfine, Inc. as part of a standard equity compensation arrangement.
Summary
- Director Jonathan M. Rothberg received a grant of 157,700 stock options on May 22, 2026.
- The options have an exercise price of $1.49 per share.
- The options are set to expire on May 22, 2036.
- Vesting is scheduled to occur on the date of the company's next regular annual stockholders meeting, contingent upon continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation rather than a change in company fundamentals.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential future dilution of existing shareholders upon the exercise of these options.
Risks
- The value of the options is dependent on the future market performance of Hyperfine's Class A Common Stock.
- Vesting is subject to the continued service of the director.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an equity grant to a director.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term oversight and strategic alignment in the medical technology sector.
Comparison to Industry Standards
- The grant of stock options to non-employee directors is a common practice among small-cap medical device companies to preserve cash while providing competitive compensation packages.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of 157,700 stock options to Director Jonathan M. Rothberg. | 05/22/2026 | Standard alignment of director compensation with shareholder interests. |
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of options at the next regular annual stockholders meeting.
Key Dates
| Date | Description |
|---|---|
| 05/22/2026 | Transaction date of the stock option grant and expiration date of the options (10-year term). |
Keywords
Hyperfine, HYPR, Form 4, Insider Trading, Stock Options, Jonathan Rothberg, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.